Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Public ClinicalTrials.gov record NCT02014558. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study was to assess the safety and tolerability, including the maximum tolerated dose, of gilteritinib in participants with relapsed or treatment-refractory acute myeloid leukemia (AML). This study also determined the pharmacokinetic (PK) parameters of gilteritinib.
Study identification
- NCT ID
- NCT02014558
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 265 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 9, 2013 (Actual)
- Primary completion
- Aug 4, 2017 (Actual)
- Completion
- Mar 7, 2018 (Actual)
- Last update posted
- Dec 3, 2024
2013 – 2018
United States locations
- U.S. sites
- 23
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site US10021 | Birmingham | Alabama | 35294 | — |
| Site US10023 | Scottsdale | Arizona | 85259 | — |
| Site US10022 | Duarte | California | 91010 | — |
| Site US10008 | Los Angeles | California | 90095-1678 | — |
| Site US10005 | San Francisco | California | 94143 | — |
| Site US10001 | Chicago | Illinois | 60611 | — |
| Site US10015 | Chicago | Illinois | 60637 | — |
| Site US10012 | Baltimore | Maryland | 21201 | — |
| Site US10003 | Baltimore | Maryland | 21287 | — |
| Site US10006 | Minneapolis | Minnesota | 55455 | — |
| Site US10011 | Rochester | Minnesota | 55905 | — |
| Site US10020 | Hackensack | New Jersey | 07601 | — |
| Site US10010 | Buffalo | New York | 14263 | — |
| Site US10009 | New York | New York | 10022 | — |
| Site US10013 | New York | New York | 10032 | — |
| Site US10019 | New York | New York | 10065 | — |
| Site US10014 | Cleveland | Ohio | 44195 | — |
| Site US10018 | Hershey | Pennsylvania | 17033 | — |
| Site US10004 | Philadelphia | Pennsylvania | 19104 | — |
| Site US10017 | Charleston | South Carolina | 29425-8900 | — |
| Site US10007 | Nashville | Tennessee | 37232 | — |
| Site US10002 | Houston | Texas | 77030 | — |
| Site US10026 | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02014558, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2024 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02014558 live on ClinicalTrials.gov.